We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
InVixa Inc, a biopharmaceutical start-up developing inhaled statins to treat COVID-19, announced today an exclusive licensing deal with the University of California, Davis, a leading US academic and medical institution.